Dr. René C.-Gaudreault, l. pharm., PhD, is a senior researcher at the Centre de recherche du CHU de Québec-Laval University. He is the director of a medicinal chemistry laboratory based at the Hôpital Saint-François d’Assise. In addition, he is a full professor in the Department of molecular medicine at the Laval University School of Medicine. Dr. C.-Gaudreault is the author and coauthor of over 100 publications in peer-reviewed journals, and the inventor and co-inventor of numerous patents. He is the recipient of several prizes and distinctions, notably the Frisen-Rygel Medal for an outstanding Canadian academic discovery leading to uniquely positioned commercialization opportunities. His research programs mainly focus on the design and development of new anti-inflammatory, antipsoriatic, and anticancer drugs for personalized therapies.

Development of new anticancer and anti-inflammatory drugs for personalized medicine

Cancer and inflammation-based diseases are major health concerns in Canada and worldwide. Despite important medical breakthroughs over the past 75 years, few treatments are efficient and devoid of deleterious effects. Consequently, new drugs and treatments are required to improve both the quality of life and the life expectancy of patients. It is in this context that Dr. Gaudreault’s laboratory is involved in the drug design and development of new anticancer agents and their prodrugs, and non-steroidal anti-inflammatory agents exhibiting suitable biopharmaceutical and pharmacodynamic properties for preclinical and clinical studies. In addition, Dr. Gaudreault’s team is involved in the determination of their mechanisms of action and their potential therapeutical applications, using various cellular and molecular pharmacology approaches to support the design and the optimization of the next generations of molecules. Dr. Gaudreault’s research programs involve several interrelated and complementary disciplines, including molecular design and modelling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to new and efficient drugs for applications in personalized medicine.

Hôpital Saint-François d'Assise
10, rue de l'Espinay
E0-171
Québec, Québec
Canada G1L 3L5
55 entries « 3 of 6 »

Fortin S, Wei L, Moreau E, Lacroix J, Cote MF, Petitclerc E, Kotra LP, C-Gaudreault R

Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4.

Journal Article

J Med Chem, 54 (13), pp. 4559-80, 2011, ISSN: 0022-2623.

Abstract | Links:

Trzeciakiewicz A, Fortin S, Moreau E, C-Gaudreault R, Lacroix J, Chambon C, Communal Y, Chezal JM, Miot-Noirault E, Bouchon B, Degoul F

Intramolecular cyclization of N-phenyl N'(2-chloroethyl)ureas leads to active N-phenyl-4,5-dihydrooxazol-2-amines alkylating β-tubulin Glu198 and prohibitin Asp40.

Journal Article

Biochem Pharmacol, 81 (9), pp. 1116-23, 2011, ISSN: 0006-2952.

Abstract | Links:

Fortin S, Bouchon B, Chambon C, Lacroix J, Moreau E, Chezal JM, Degoul F, C-Gaudreault R

Characterization of the covalent binding of N-phenyl-N'-(2-chloroethyl)ureas to {beta}-tubulin: importance of Glu198 in microtubule stability.

Journal Article

J Pharmacol Exp Ther, 336 (2), pp. 460-7, 2011, ISSN: 0022-3565.

Abstract | Links:

Patenaude A, Fortin JS, Deschenes R, Cote MF, Lacroix J, C-Gaudreault R, Petitclerc E

Chloroethyl urea derivatives block tumour growth and thioredoxin-1 nuclear translocation.

Journal Article

Can J Physiol Pharmacol, 88 (11), pp. 1102-14, 2010, ISSN: 0008-4212.

Abstract | Links:

Fortin S, Moreau E, Lacroix J, Cote MF, Petitclerc E, C-Gaudreault R

Synthesis, antiproliferative activity evaluation and structure-activity relationships of novel aromatic urea and amide analogues of N-phenyl-N'-(2-chloroethyl)ureas.

Journal Article

Eur J Med Chem, 45 (7), pp. 2928-37, 2010, ISSN: 0223-5234.

Abstract | Links:

Mounetou E, Miot-Noirault E, Gaudreault RC, Madelmont JC

N-4-iodophenyl-N'-2-chloroethylurea, a novel potential anticancer agent with colon-specific accumulation: radioiodination and comparative in vivo biodistribution profiles.

Journal Article

Invest New Drugs, 28 (2), pp. 124-31, 2010, ISSN: 0167-6997.

Abstract | Links:

Fortin S, Lacroix J, Cote MF, Moreau E, Petitclerc E, C-Gaudreault R

Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site.

Journal Article

Biol Proced Online, 12 (1), pp. 113-7, 2010.

Abstract | Links:

Bawolak MT, Fortin S, Bouthillier J, Adam A, Gera L, C-Gaudreault R, Marceau F

Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors.

Journal Article

Br J Pharmacol, 158 (5), pp. 1375-86, 2009, ISSN: 0007-1188.

Abstract | Links:

Fortin S, Wei L, Moreau E, Labrie P, Petitclerc E, Kotra LP, C-Gaudreault R

Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin.

Journal Article

Bioorg Med Chem, 17 (10), pp. 3690-7, 2009, ISSN: 0968-0896.

Abstract | Links:

Labbe JF, Cronier F, C-Gaudreault R, Auger M

Spectroscopic characterization of DMPC/DOTAP cationic liposomes and their interactions with DNA and drugs.

Journal Article

Chem Phys Lipids, 158 (2), pp. 91-101, 2009, ISSN: 0009-3084.

Abstract | Links:

55 entries « 3 of 6 »
Signaler des ajouts ou des modifications

Active projects

  • Accélérer et rendre plus accessibles les tests précliniques en chimiothérapie et la radiothérapie du cancer, en utilisant le modèle de l'oeuf et des stratégies d'impression 3D, Subvention, Fonds de recherche du Québec - Nature et technologies, Projet de recherche en équipe, from 2020-04-01 to 2023-03-31
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
  • Validation of Highly Potent Substituted Phenyl Alkylureas as Antipsoriatic Agents, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2021-03-31

Recently finished projects

  • Comprendre le rôle des cellules immunitaires dans le psoriasis grâce au génie tissulaire, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-04-01 to 2020-03-31
  • Les phénylimidazolidones, de nouvelles molécules pour le traitement personnalisé des cancers du sein hormono- et chimiorésistants: du laboratoire vers la clinique., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2019-07-30
  • Substituted phenyl alkylureas as new potent antipsoriatic drugs: Mechanism of action and structure-activity relationships., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30
Data provided by the Université Laval research projects registery